First Reported Use of Radiofrequency Identification (RFID) Technique for Targeted Excision of Suspicious Axillary Lymph Nodes in Early Stage Breast Cancer - Evaluation of Feasibility and Review of Current Recommendations

Overview

Journal In Vivo

Specialty Oncology

Date 2020 May 2

PMID 32354911

Citations 14

Authors

Wolfram Malter

Christian Eichler

Bettina Hanstein

Peter Mallmann

Johannes Holtschmidt

Affiliations

Soon will be listed here.

Abstract

Background/aim: The purpose of this study was to evaluate, whether radio frequency identification (RFID) labeling of axillary lymph nodes (LNs) for the use of targeted resection is feasible in primary breast cancer patients with suspicious LNs.

Patients And Methods: We analyzed 10 consecutive patients where RFID technique was used for intraoperative detection of suspicious LNs without preceding neoadjuvant chemotherapy (NACT). We compared the specifics of these procedures to 10 consecutive sentinel lymph node biopsies (SLNB) in the cN0 situation.

Results: Intraoperative detection rate (DR) for the RFID-labeled target lymph node (TLN) was 100%. Perioperative complications were infrequent and comparable to SLNB. Average time for location of the RFID labeled TLN was quicker than for the SLN. In 71.4% the chip bearing TLN equaled a SLN.

Conclusion: The use of the RFID technique for intraoperative localization of axillary LNs for targeted excision seems feasible. RFID technique for targeted axillary dissection (TAD) following NACT should be investigated in a prospective manner.

Citing Articles

Wire-Free Targeted Axillary Dissection: A Pooled Analysis of 1300+ Cases Post-Neoadjuvant Systemic Therapy in Node-Positive Early Breast Cancer.

Varghese J, Patani N, Wazir U, Novintan S, Michell M, Malhotra A Cancers (Basel). 2024; 16(12).

PMID: 38927878 PMC: 11201777. DOI: 10.3390/cancers16122172.

Early Breast Cancer: Could Combined LOCalizer and Ultrasound Localization Replace the Metallic Wire? A Multicentric Study.

Parisi S, Gambardella C, Santoriello A, Ruggiero R, Iovino F, Fisone F J Clin Med. 2024; 13(6).

PMID: 38541938 PMC: 10971727. DOI: 10.3390/jcm13061713.

Image-guided Localization Techniques for Nonpalpable Breast Lesions: An Opportunity for Multidisciplinary Patient-centered Care.

Davis K, Raybon C, Monga N, Waheed U, Michaels A, Henry C J Breast Imaging. 2024; 3(5):542-555.

PMID: 38424951 PMC: 11256989. DOI: 10.1093/jbi/wbab061.

Feasibility and accuracy of targeted axillary dissection in breast cancer patients; single center experience.

Kaya C, Burcu B, Cetinoglu I, Ucak R, Cerekci E, Sahin C Front Surg. 2024; 10:1332142.

PMID: 38269392 PMC: 10806091. DOI: 10.3389/fsurg.2023.1332142.

Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study.

Hartmann S, Banys-Paluchowski M, Stickeler E, de Boniface J, Gentilini O, Kontos M Breast Cancer Res Treat. 2023; 202(3):497-504.

PMID: 37684426 PMC: 10564814. DOI: 10.1007/s10549-023-07100-0.

References

Simons J, van Pelt M, Marinelli A, Straver M, Zeillemaker A, Pereira Arias-Bouda L . Excision of both pretreatment marked positive nodes and sentinel nodes improves axillary staging after neoadjuvant systemic therapy in breast cancer. Br J Surg. 2019; 106(12):1632-1639. PMC: 6856822. DOI: 10.1002/bjs.11320. View

Houssami N, Ciatto S, Turner R, Cody 3rd H, Macaskill P . Preoperative ultrasound-guided needle biopsy of axillary nodes in invasive breast cancer: meta-analysis of its accuracy and utility in staging the axilla. Ann Surg. 2011; 254(2):243-51. DOI: 10.1097/SLA.0b013e31821f1564. View

Malter W, Holtschmidt J, Thangarajah F, Mallmann P, Krug B, Warm M . First Reported Use of the Faxitron LOCalizer™ Radiofrequency Identification (RFID) System in Europe - A Feasibility Trial, Surgical Guide and Review for Non-palpable Breast Lesions. In Vivo. 2019; 33(5):1559-1564. PMC: 6754990. DOI: 10.21873/invivo.11637. View

Mamtani A, Barrio A, King T, Van Zee K, Plitas G, Pilewskie M . How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study. Ann Surg Oncol. 2016; 23(11):3467-3474. PMC: 5070651. DOI: 10.1245/s10434-016-5246-8. View

Flores-Funes D, Aguilar-Jimenez J, Martinez-Galvez M, Ibanez-Ibanez M, Carrasco-Gonzalez L, Gil-Izquierdo J . Validation of the targeted axillary dissection technique in the axillary staging of breast cancer after neoadjuvant therapy: Preliminary results. Surg Oncol. 2019; 30:52-57. DOI: 10.1016/j.suronc.2019.05.019. View

Mansel R, Fallowfield L, Kissin M, Goyal A, Newcombe R, Dixon J . Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst. 2006; 98(9):599-609. DOI: 10.1093/jnci/djj158. View

Lyman G, Temin S, Edge S, Newman L, Turner R, Weaver D . Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014; 32(13):1365-83. DOI: 10.1200/JCO.2013.54.1177. View

DiNome M, Kusske A, Attai D, Fischer C, Hoyt A . Microchipping the breast: an effective new technology for localizing non-palpable breast lesions for surgery. Breast Cancer Res Treat. 2019; 175(1):165-170. DOI: 10.1007/s10549-019-05143-w. View

Bossuyt V, Provenzano E, Symmans W, Boughey J, Coles C, Curigliano G . Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration. Ann Oncol. 2015; 26(7):1280-91. PMC: 4804123. DOI: 10.1093/annonc/mdv161. View

10.

Veronesi U, Paganelli G, Viale G, Luini A, Zurrida S, Galimberti V . A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med. 2003; 349(6):546-53. DOI: 10.1056/NEJMoa012782. View

11.

Tadros A, Yang W, Krishnamurthy S, Rauch G, Smith B, Valero V . Identification of Patients With Documented Pathologic Complete Response in the Breast After Neoadjuvant Chemotherapy for Omission of Axillary Surgery. JAMA Surg. 2017; 152(7):665-670. PMC: 5547923. DOI: 10.1001/jamasurg.2017.0562. View

12.

Coufal O, Zapletal O, Gabrielova L, Fabian P, Schneiderova M . Targeted axillary dissection and sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy - a retrospective study. Rozhl Chir. 2019; 97(12):551-557. View

13.

von Minckwitz G, Huang C, Mano M, Loibl S, Mamounas E, Untch M . Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer. N Engl J Med. 2018; 380(7):617-628. DOI: 10.1056/NEJMoa1814017. View

14.

Stachs A, Gode K, Hartmann S, Stengel B, Nierling U, Dieterich M . Accuracy of axillary ultrasound in preoperative nodal staging of breast cancer - size of metastases as limiting factor. Springerplus. 2013; 2:350. PMC: 3733074. DOI: 10.1186/2193-1801-2-350. View

15.

van Nijnatten T, Simons J, Smidt M, van der Pol C, van Diest P, Jager A . A Novel Less-invasive Approach for Axillary Staging After Neoadjuvant Chemotherapy in Patients With Axillary Node-positive Breast Cancer by Combining Radioactive Iodine Seed Localization in the Axilla With the Sentinel Node Procedure (RISAS): A.... Clin Breast Cancer. 2017; 17(5):399-402. DOI: 10.1016/j.clbc.2017.04.006. View

16.

Lyman G, Somerfield M, Bosserman L, Perkins C, Weaver D, Giuliano A . Sentinel Lymph Node Biopsy for Patients With Early-Stage Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2016; 35(5):561-564. DOI: 10.1200/JCO.2016.71.0947. View

17.

Rao R, Euhus D, Mayo H, Balch C . Axillary node interventions in breast cancer: a systematic review. JAMA. 2013; 310(13):1385-94. DOI: 10.1001/jama.2013.277804. View

18.

Dominici L, Negron Gonzalez V, Buzdar A, Lucci A, Mittendorf E, Le-Petross H . Cytologically proven axillary lymph node metastases are eradicated in patients receiving preoperative chemotherapy with concurrent trastuzumab for HER2-positive breast cancer. Cancer. 2010; 116(12):2884-9. PMC: 4361091. DOI: 10.1002/cncr.25152. View

19.

Ashikaga T, Krag D, Land S, Julian T, Anderson S, Brown A . Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol. 2010; 102(2):111-8. PMC: 3072246. DOI: 10.1002/jso.21535. View

20.

Caudle A, Yang W, Krishnamurthy S, Mittendorf E, Black D, Gilcrease M . Improved Axillary Evaluation Following Neoadjuvant Therapy for Patients With Node-Positive Breast Cancer Using Selective Evaluation of Clipped Nodes: Implementation of Targeted Axillary Dissection. J Clin Oncol. 2016; 34(10):1072-8. PMC: 4933133. DOI: 10.1200/JCO.2015.64.0094. View